Mark Hahn Biography and Net Worth

From January 2018 until its acquisition by Swedish Orphan Biovitrum for up to $915 million in November 2019, Mr Hahn served as CFO of Dova Pharmaceuticals, a US company developing therapeutics for rare diseases, where he was instrumental in raising capital and in the launch of Dova’s first commercial product. From 2010 until its acquisition by Melinta Therapeutics in November 2017, Mr Hahn was CFO of Cempra where he led the company’s IPO and several subsequent follow-on offerings. Prior to Cempra, Mr Hahn was the CFO of several other public and private companies. Mr Hahn began his career at Ernst & Young. He received a Bachelor of Business Administration degree in Accounting and Finance from the University of Wisconsin-Milwaukee and is a certified public accountant in Maryland and North Carolina.

What is Mark W. Hahn's net worth?: The estimated net worth of Mark W. Hahn is at least $252.45 million as of August 3rd, 2023. Mr. Hahn owns 15,679,864 shares of Verona Pharma stock worth more than $252,445,810 as of April 18th. This net worth evaluation does not reflect any other assets that Mr. Hahn may own. Additionally, Mr. Hahn receives a salary of $858,290.00 as CFO at Verona Pharma. Learn More about Mark W. Hahn's net worth.
How old is Mark W. Hahn?: Mr. Hahn is currently 61 years old. There are 4 older executives and no younger executives at Verona Pharma. The oldest executive at Verona Pharma is Dr. Kathleen A. Rickard M.D., Chief Medical Officer, who is 66 years old. Learn More on Mark W. Hahn's age.
What is Mark W. Hahn's salary?: As the CFO of Verona Pharma plc, Mr. Hahn earns $858,290.00 per year. The highest earning executive at Verona Pharma is Dr. David S. Zaccardelli Pharm.D., President, CEO & Executive Director, who commands a salary of $1,270,000.00 per year. Learn More on Mark W. Hahn's salary.
How do I contact Mark W. Hahn?: The corporate mailing address for Mr. Hahn and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Mark W. Hahn's contact information.
Has Mark W. Hahn been buying or selling shares of Verona Pharma?: Mark W. Hahn has not been actively trading shares of Verona Pharma during the last quarter. Most recently, Mark W. Hahn sold 117,272 shares of the business's stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $2.54, for a transaction totalling $297,870.88. Following the completion of the sale, the chief financial officer now directly owns 15,679,864 shares of the company's stock, valued at $39,826,854.56. Learn More on Mark W. Hahn's trading history.
Who are Verona Pharma's active insiders?: Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.
Are insiders buying or selling shares of Verona Pharma?: In the last year, Verona Pharma insiders bought shares 2 times. They purchased a total of 193,736 shares worth more than $378,874.24. In the last year, insiders at the sold shares 19 times. They sold a total of 2,164,281 shares worth more than $13,411,301.36. The most recent insider tranaction occured on November, 20th when Director Martin Edwards bought 33,736 shares worth more than $62,074.24. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.
Information on this page was last updated on 11/20/2023.

Mark W. Hahn Insider Trading History at Verona Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/3/2023	Sell	117,272	$2.54	$297,870.88	15,679,864
8/1/2023	Sell	105,944	$2.68	$283,929.92	15,870,840
5/1/2023	Sell	455,528	$2.58	$1,175,262.24	15,976,784
2/1/2023	Sell	413,168	$2.56	$1,057,710.08	16,432,312
8/1/2022	Sell	13,168	$0.70	$9,217.60	14,913,496
5/3/2022	Sell	12,512	$0.50	$6,256.00	15,381,520
2/2/2022	Sell	10,416	$0.76	$7,916.16
11/2/2021	Sell	10,416	$0.65	$6,770.40
8/2/2021	Sell	10,416	$0.77	$8,020.32	16,466,800
3/1/2021	Sell	26,728	$1.14	$30,469.92

Mark W. Hahn Buying and Selling Activity at Verona Pharma

Verona Pharma Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $16.10

$15.94

$16.45

50 Day Range

MA: $16.53

$15.30

$18.19

2 Week Range

Now: $16.10

$11.83

$23.81

Volume

489,991 shs

Average Volume

498,215 shs

Market Capitalization

$1.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

Mark Hahn Biography and Net Worth

What is Mark W. Hahn's net worth?

How old is Mark W. Hahn?

What is Mark W. Hahn's salary?

How do I contact Mark W. Hahn?

Has Mark W. Hahn been buying or selling shares of Verona Pharma?

Who are Verona Pharma's active insiders?

Are insiders buying or selling shares of Verona Pharma?